Categories AlphaGraphs, Earnings, Technology
DocuSign (DOCU) Q1 profit rises in double-digits; revenue up 7%
DocuSign, Inc. (NASDAQ: DOCU) has reported a double-digit growth in adjusted earnings for the first quarter of 2025. Revenues of the eSignature service provider increased by 7%.
First-quarter revenues increased to $709.6 million from $661.4 million in the same period last year. Subscription revenue advanced by 8%, while Professional Service revenue decreased by 18% during the three months.
At $0.82 per share, adjusted earnings were up 14% year-over-year. First-quarter net profit, including special items, was $33.8 million or $0.16 per share, compared to $0.54 million or $0.00 per share in the corresponding period of 2024.
For the second quarter of 2025, the management expects revenues to be in the range of $725 million to $729 million. Full-year 2025 revenue is estimated to be between $2.920 billion and $2.932 billion.
Prior Performance
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
Key takeaways from JM Smucker’s (SJM) Q4 2025 earnings report
Shares of The J.M. Smucker Co. (NYSE: SJM) plunged 15% on Tuesday after the company delivered mixed results for the fourth quarter of 2025. While earnings came ahead of expectations,
J.M. Smucker (SJM) Q4 2025 Earnings: Key financials and quarterly highlights
The J.M. Smucker Co. (NYSE: SJM) reported its fourth quarter 2025 earnings results today. Net sales was $2.1 billion, down 3% year-over-year. Comparable net sales decreased 1%. Net loss was
Plus Therapeutics CEO: Lead candidate REYOBIQ demonstrates strong safety and efficacy in early trials
Plus Therapeutics (NASDAQ: PSTV) is a pharmaceutical company engaged in the development of targeted radiotherapeutics for difficult-to-treat cancers. Currently, it is advancing a pipeline of product candidates with lead programs
